Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	[1]
Current assets:
Cash and cash equivalents	$ 21,505	$ 24,780
Short-term investments	101,668	115,438
Prepaid and other current assets	3,658	5,928
Total current assets	126,831	146,146
Property and equipment, net	142	165
Operating lease right-of-use asset	355	386
Other assets	450	443
Total assets	127,778	147,140
Current liabilities:
Accounts payable	3,029	6,112
Accrued research and development	5,374	4,349
Other accrued liabilities	4,480	5,694
Operating lease liability, current portion	161	160
Total current liabilities	13,044	16,315
Operating lease liability, net of current portion	219	252
Other long-term liabilities	64	69
Total liabilities	13,327	16,636
Commitments and contingencies
Stockholders' equity:
Common Stock, $0.001 par value; 250,000,000 shares authorized as of March 31, 2022 and December 31, 2021, respectively; 26,526,878 shares (comprised of 18,799,408 shares of common stock and 7,727,470 shares of non-voting common stock) and 26,475,812 shares (comprised of 18,748,342 shares of common stock and 7,727,470 shares of non-voting common stock) issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	27	27
Additional paid-in capital	222,171	220,530
Accumulated other comprehensive loss	(389)	(89)
Accumulated deficit	(107,358)	(89,964)
Total stockholders' equity	114,451	130,504
Total liabilities and stockholders' equity	$ 127,778	$ 147,140

[1] The balance sheet at December 31, 2021 has been derived from the audited financial statements included in Rain Therapeutics Inc.’s Annual Report on Form 10-K filed on March 3, 2022.